These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 29870600)
1. Analytical Aspects of Biopharmaceuticals and their Study by Mass Spectrometry. David V; Borbala D; Laroly V; Laszlo D; Istvan A; Imre K; Krisztina L Acta Pharm Hung; 2016; 86(4):141-150. PubMed ID: 29870600 [TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry. Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058 [TBL] [Abstract][Full Text] [Related]
3. Recent advancements, challenges, and practical considerations in the mass spectrometry-based analytics of protein biotherapeutics: A viewpoint from the biosimilar industry. Háda V; Bagdi A; Bihari Z; Timári SB; Fizil Á; Szántay C J Pharm Biomed Anal; 2018 Nov; 161():214-238. PubMed ID: 30205300 [TBL] [Abstract][Full Text] [Related]
4. Top-down mass spectrometry and hydrogen/deuterium exchange for comprehensive structural characterization of interferons: implications for biosimilars. Pan J; Borchers CH Proteomics; 2014 May; 14(10):1249-58. PubMed ID: 24574185 [TBL] [Abstract][Full Text] [Related]
5. Analysis of biological therapeutic agents and biosimilars. Phinney K Anal Bioanal Chem; 2014 Oct; 406(26):6539. PubMed ID: 25190012 [No Abstract] [Full Text] [Related]
6. Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry. Sorensen M; Harmes DC; Stoll DR; Staples GO; Fekete S; Guillarme D; Beck A MAbs; 2016 Oct; 8(7):1224-1234. PubMed ID: 27362833 [TBL] [Abstract][Full Text] [Related]
7. Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry. Zhu L; Guo Q; Guo H; Liu T; Zheng Y; Gu P; Chen X; Wang H; Hou S; Guo Y MAbs; 2014; 6(6):1474-85. PubMed ID: 25484062 [TBL] [Abstract][Full Text] [Related]
9. Discovery and characterization of antibody variants using mass spectrometry-based comparative analysis for biosimilar candidates of monoclonal antibody drugs. Li W; Yang B; Zhou D; Xu J; Ke Z; Suen WC J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul; 1025():57-67. PubMed ID: 27214604 [TBL] [Abstract][Full Text] [Related]
10. Hybrid mass spectrometry approaches in glycoprotein analysis and their usage in scoring biosimilarity. Yang Y; Liu F; Franc V; Halim LA; Schellekens H; Heck AJ Nat Commun; 2016 Nov; 7():13397. PubMed ID: 27824045 [TBL] [Abstract][Full Text] [Related]
11. Integrated Bottom-Up and Top-Down Liquid Chromatography-Mass Spectrometry for Characterization of Recombinant Human Growth Hormone Degradation Products. Wang YA; Wu D; Auclair JR; Salisbury JP; Sarin R; Tang Y; Mozdzierz NJ; Shah K; Zhang AF; Wu SL; Agar JN; Love JC; Love KR; Hancock WS Anal Chem; 2017 Dec; 89(23):12771-12777. PubMed ID: 29096433 [TBL] [Abstract][Full Text] [Related]
12. MS in the analysis of biosimilars. Singleton CA Bioanalysis; 2014; 6(12):1627-37. PubMed ID: 25077624 [TBL] [Abstract][Full Text] [Related]
13. N-glycan Analysis in Molecular Medicine: Innovator and Biosimilar Protein Therapeutics. Borza B; Hajba L; Guttman A Curr Mol Med; 2020; 20(10):828-839. PubMed ID: 33272172 [TBL] [Abstract][Full Text] [Related]
14. Conformation and dynamics of biopharmaceuticals: transition of mass spectrometry-based tools from academe to industry. Kaltashov IA; Bobst CE; Abzalimov RR; Berkowitz SA; Houde D J Am Soc Mass Spectrom; 2010 Mar; 21(3):323-37. PubMed ID: 19963397 [TBL] [Abstract][Full Text] [Related]
15. A View on the Importance of "Multi-Attribute Method" for Measuring Purity of Biopharmaceuticals and Improving Overall Control Strategy. Rogers RS; Abernathy M; Richardson DD; Rouse JC; Sperry JB; Swann P; Wypych J; Yu C; Zang L; Deshpande R AAPS J; 2017 Nov; 20(1):7. PubMed ID: 29192343 [TBL] [Abstract][Full Text] [Related]
16. Identification of Low-Level Product-Related Variants in Filgrastim Products Presently Available in Highly Regulated Markets. Hausberger A; Lamanna WC; Hartinger M; Seidl A; Toll H; Holzmann J BioDrugs; 2016 Jun; 30(3):233-42. PubMed ID: 27026103 [TBL] [Abstract][Full Text] [Related]
17. Application of new analytical technology to the production of a "well-characterized biological". Apffel A; Chakel J; Udiavar S; Swedberg S; Hancock WS; Souders C; Pungor E Dev Biol Stand; 1998; 96():11-25. PubMed ID: 9890511 [TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of molecular targets of natural products by mass spectrometry. Cheng KW; Wong CC; Wang M; He QY; Chen F Mass Spectrom Rev; 2010; 29(1):126-55. PubMed ID: 19319922 [TBL] [Abstract][Full Text] [Related]
19. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors]. Jahnz-Rozyk K; Wiesik-Szewczyk E; Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192 [TBL] [Abstract][Full Text] [Related]
20. Characterization and QC of biopharmaceuticals by MS-based 'multi-attribute method': advantages and challenges. Zhang Y; Guo J Bioanalysis; 2017 Mar; 9(6):499-502. PubMed ID: 28207284 [No Abstract] [Full Text] [Related] [Next] [New Search]